Akebia Therapeutics Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialy… Read more
Akebia Therapeutics Inc (AX9) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.676x
Based on the latest financial reports, Akebia Therapeutics Inc (AX9) has a cash flow conversion efficiency ratio of 0.676x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€28.11 Million) by net assets (€41.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Akebia Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Akebia Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Akebia Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akebia Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Fasten Co Ltd
SHE:000890
|
0.423x |
|
Medigen Vaccine Biologics
TWO:6547
|
-0.003x |
|
Boston Omaha Corp
NYSE:BOC
|
0.009x |
|
Meitav Trade Inv Ltd
TA:MTRD
|
N/A |
|
Jiangsu Flag Chemical Industry Co Ltd
SHE:300575
|
0.073x |
|
Atlanticus Holdings Corporation
NASDAQ:ATLC
|
0.172x |
|
Great Taipei Gas Corp
TW:9908
|
0.056x |
|
Nova Minerals Limited
NASDAQ:NVA
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Akebia Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Akebia Therapeutics Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-49.19 Million | €-40.66 Million | 0.827x | +8.12% |
| 2023-12-31 | €-30.58 Million | €-23.38 Million | 0.765x | +109.76% |
| 2022-12-31 | €9.34 Million | €-73.15 Million | -7.831x | -136.67% |
| 2021-12-31 | €76.46 Million | €-252.97 Million | -3.309x | -642.18% |
| 2020-12-31 | €247.62 Million | €-110.39 Million | -0.446x | +31.64% |
| 2019-12-31 | €394.76 Million | €-257.44 Million | -0.652x | -325.38% |
| 2018-12-31 | €635.93 Million | €-97.49 Million | -0.153x | +67.42% |
| 2017-12-31 | €119.33 Million | €-56.16 Million | -0.471x | -155.36% |
| 2016-12-31 | €68.12 Million | €57.91 Million | 0.850x | +312.48% |
| 2015-12-31 | €131.00 Million | €-52.41 Million | -0.400x | -- |